Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial

被引：0
|
作者：
Mao-Draayers, Yang [2 ]
Wu, Qi
Wang, Qin
Dowling, Catherine
Lundy, Steven [3 ,4 ]
Segal, Benjamin [2 ]
Wallstrom, Wallstrom [1 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Univ Michigan, Dept Neurol, Ann Arbor, MI USA
[3] Univ Michigan, Sch Med, Dept Internal Med, Div Rheumatol, Ann Arbor, MI USA
[4] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P3.046
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
    Mao-Draayer, Yang
    Wu, Qi
    Wang, Qin
    Lundy, Steve K.
    Dowling, Catherine
    Segal, Benjamin Matthew M.
    Fox, David
    Wallstroem, Erik
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 12 - 12
  • [2] Baseline immunological profile in secondary progressive multiple sclerosis patients of Phase III EXPAND Trial
    Mao-Draayer, Yang
    Wu, Qi
    Wang, Qin
    Dowling, Catherine
    Lundy, Steve K.
    Segal, Benjamin Matthew M.
    Wallstroem, Erik
    Fox, David A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 13 - 13
  • [3] Baseline Immunophenotyping and Gene Expression Analysis in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
    Mao-Draayer, Yang
    Wu, Qi
    Wang, Qin
    Dowling, Catherine
    Mao, Guangmei
    Lundy, Steven K.
    Segal, Benjamin Matthew M.
    Wallstroem, Erik
    Fox, David A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 68 - 68
  • [4] Comparative Immunophenotyping and Gene Expression Analysis of Benign and Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
    Mao-Draayer, Yang
    Wu, Qi
    Wang, Qin
    Mao, Guangmei
    Dowling, Catherine
    Lundy, Steven
    Wallstrom, Erik
    Fox, David
    [J]. NEUROLOGY, 2017, 88
  • [5] THE MS-STAT TRIAL: A PHASE II TRIAL OF HIGH-DOSE SIMVASTATIN FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: BASELINE TRIAL PROFILE
    Chataway, J.
    Anderson, V.
    Chan, D.
    Frost, C.
    Hunter, K.
    Kallis, C.
    Greenwood, J.
    Schuerer, N.
    Alsanousi, A.
    Nicholas, R.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (11): : E55 - E55
  • [6] Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
    Kappos, Ludwig
    Bar-Or, Amit
    Cree, Bruce
    Fox, Robert
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Lam, Elaine
    Pohlmann, Harold
    Zhang-Auberson, Lixin
    Dandekar, Atul
    Wallstroem, Erik
    [J]. NEUROLOGY, 2013, 80
  • [7] Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Lam, E.
    Pohlmann, H.
    Zhang-Auberson, L.
    Dandekar, A.
    Wallstrom, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 927 - 928
  • [8] Immunological aspects of secondary progressive multiple sclerosis
    Weiner, LP
    Kachuck, NJ
    Gilmore, W
    Lund, B
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2002, 8 (01) : 83 - 84
  • [9] Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis
    McAdams, Matthew
    Stankiewicz, James M.
    Weiner, Howard L.
    Chitnis, Tanuja
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 54
  • [10] Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis
    Kappos, Ludwig
    Bar-Or, Amit
    Cree, Bruce
    Fox, Robert
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Bhasin, Priya
    Arnould, Sophie
    Sidorenko, Tatiana
    Wallstroem, Erik
    [J]. NEUROLOGY, 2016, 86
12345